← Leaderboards
Elizabeth Chiao
Baylor College Of Medicine
$12,842,422
Attributed
$21,672,512
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.7M · FY2006–25$5M$3.8M$2.5M$1.3M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$24,822,633 · 9
By mechanism
R01$20,643,479 · 6
U54$3,385,921 · 2
K23$793,233 · 1
Top collaborators
- Ashish A. Deshmukh8 shared
- Keith Magnus Sigel8 shared
- Sharmila Anandasabapathy7 shared
- Vanderlei Bagnato6 shared
- Regis Kreitchmann6 shared
- Cesaltina Ferreira Lorenzoni6 shared
- Rebecca Rae Richards-Kortum6 shared
- Kathleen Schmeler6 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Jane R Montealegre$3,820,707
- Robert J Volk$1,311,195
- William Thomas Shearer$34,592,326
- James A Herd$71,904
- Eva H Clark$955,291
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsPersonsMalignant Neoplasm Of Cervix UteriDiagnosisIncidenceMalignant Neoplasm Of AnusPreventionCervicalAnusRisk FactorsHiv InfectionsHigh RiskWomanEpidemiologyGeneral PopulationAntiretroviral TherapyCostMalignant Squamous Cell NeoplasmReportingLesionMortalityCohort StudiesHuman Papilloma Virus InfectionMorbidity - Disease Rate
Grant awards (43)
The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors$1,106,183
R01 · FY2025 · CA
The Effectiveness of Automated Multimodal Imaging in High Grade Squamous Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV: An International Trial$942,063
R01 · FY2025 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$807,549
R01 · FY2025 · CA
Optimizing Treatment of Prostate Cancer in Men living with HIV$669,481
R01 · FY2025 · CA
The AVANÃO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV$647,289
U54 · FY2025 · CA
The AVANÃO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV$246,592
U54 · FY2025 · CA
Developmental Core$129,457
U54 · FY2025 · CA · contact PI
The AVANÃO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV$120,096
U54 · FY2025 · CA
The AVANÃO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV$45,360
U54 · FY2025 · CA
The AVANÃO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV$1,059,338
U54 · FY2024 · CA
The Effectiveness of Automated Multimodal Imaging in High Grade Squamous Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV: An International Trial$988,950
R01 · FY2024 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$808,120
R01 · FY2024 · CA
Optimizing Treatment of Prostate Cancer in Men living with HIV$669,206
R01 · FY2024 · CA
The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors$566,629
R01 · FY2024 · CA
Developmental Core$48,146
U54 · FY2024 · CA · contact PI
The AVANÃO Research Consortium: A Mozambique/Brazil/Texas Alliance to advance novel and affordable technologies for the prevention and diagnosis of cervical cancer in women living with HIV$1,031,446
U54 · FY2023 · CA
The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors$844,362
R01 · FY2023 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$807,310
R01 · FY2023 · CA
Optimizing Treatment of Prostate Cancer in Men living with HIV$720,465
R01 · FY2023 · CA
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL)Diagnosis for People Living with HIV$628,541
R01 · FY2023 · CA
Developmental Core$58,197
U54 · FY2023 · CA · contact PI
The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors$843,841
R01 · FY2022 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$808,055
R01 · FY2022 · CA
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL)Diagnosis for People Living with HIV$634,161
R01 · FY2022 · CA
The effectiveness of screening women with lower genital tract neoplasia or cancers for anal cancer precursors$916,003
R01 · FY2021 · CA
(PQ3) Addressing Cancer Treatment Disparities for Persons with HIV$807,377
R01 · FY2021 · CA
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV$637,585
R01 · FY2021 · CA
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV$645,916
R01 · FY2020 · CA
The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL) Diagnosis for People Living with HIV$696,326
R01 · FY2019 · CA · contact PI
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection$706,386
R01 · FY2018 · CA · contact PI
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection$772,521
R01 · FY2017 · CA · contact PI
(PQ3) Identifying Novel Pharmacologic Risk factors for Common Non-AIDS Defining Cancers in Individuals with Well-controlled HIV Infection$772,521
R01 · FY2016 · CA · contact PI
The Effectiveness of Screening HIV-Infected Women for Anal Cancer Precursors$553,871
R01 · FY2015 · CA · contact PI
The Effectiveness of Screening HIV-Infected Women for Anal Cancer Precursors$803,111
R01 · FY2014 · CA · contact PI
The Effectiveness of Screening HIV-Infected Women for Anal Cancer Precursors$267,428
R01 · FY2013 · CA · contact PI
The Effectiveness of Screening HIV-Infected Women for Anal Cancer Precursors$582,399
R01 · FY2012 · CA · contact PI
The Effectiveness of Screening HIV-Infected Women for Anal Cancer Precursors$637,119
R01 · FY2011 · CA · contact PI
The Epidemiologic Effects of HAART on HIV-related Anal Cancer and Anal Dysplasia$137,700
K23 · FY2010 · CA · contact PI
The Epidemiologic Effects of HAART on HIV-related Anal Cancer and Anal Dysplasia$137,700
K23 · FY2009 · CA · contact PI
The Epidemiologic Effects of HAART on HIV-related Anal Cancer and Anal Dysplasia$104,733
K23 · FY2009 · CA · contact PI
The Epidemiologic Effects of HAART on HIV-related Anal Cancer and Anal Dysplasia$137,700
K23 · FY2008 · CA · contact PI
The Epidemiologic Effects of HAART on HIV-related Anal Cancer and Anal Dysplasia$137,700
K23 · FY2007 · CA · contact PI
The Epidemiologic Effects of HAART on HIV-related Anal Cancer and Anal Dysplasia$137,700
K23 · FY2006 · CA · contact PI